Clinical trial
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
NCT00003615 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00003615 |
|---|---|
| Title | Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma |
| Official title | A Phase II Study of DAB 389 IL-2, an Interleukin-2 Fusion Toxin, for Previously Treated Stage II, III, and IV Follicular Low-Grade Non-Hodgkin's Lymphoma |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological |
| Interventions | denileukin diftitox |
| Enrollment | 77 |
| Start date | May 20, 1999 |
| Primary completion | Aug 1, 2006 |
| First posted | Feb 20, 2004 |
| Last update posted | Jun 15, 2023 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: